RECURSION PHARMACEUTICALS, INC. (RXRX) Financials
Annual revenue, profitability and per-share results for RECURSION PHARMACEUTICALS, INC., as reported in SEC filings.
Revenue · FY2025
$74.68M
▲ 26.9%YoY
Net income · FY2025
-$644.76M
▼ 39.1%YoY
Diluted EPS · FY2025
$-1.44
▲ 14.8%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $74.68M | -$644.76M | — | $-1.44 | -$378.28M | -867.9% | +26.9% |
| FY2024 | $58.84M | -$463.66M | — | $-1.69 | -$372.87M | -814.1% | +32.0% |
| FY2023 | $44.58M | -$328.07M | — | $-1.58 | -$299.74M | -785.3% | +11.9% |
| FY2022 | $39.84M | -$239.48M | — | $-1.36 | -$120.58M | -616.7% | +291.5% |
Figures as reported in RECURSION PHARMACEUTICALS, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Financials for companies related to RXRX
Never miss a RXRX filing.
Get an email when RXRX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.